Roche to Present Positive Results of Cancer Immunotherapy Programmes at ESCO 2018

 Roche to Present Positive Results of Cancer Immunotherapy Programmes at ESCO 2018

Roche to Present Positive Results of Cancer Immunotherapy Programmes at ESCO 2018

Shots:

  • Roche is presenting data that includes results assessing Tecentriq + nab-paclitaxel in Breast Cancer (P-III), Alecensa in lung cancer and Tecentriq in lung (P-III) and liver cancers(P-I)
  • Additionally, presenting Entrectinib’s (RXDX-101) positive results from P-II STARTRK-2, P-I STARTRK-1 and P-I ALKA trials for NTRK gene fusion-positive solid tumors and also received BT and PRIME medicine designation from the US FDA and EMA respectively
  • OS and PFS from P-III IMpower130 study will also be presented at ESMO 2018 assessing Tecentriq + CT (carboplatin and nab-paclitaxel) vs CT for advance NSCLC and PFS of P-III ALESIA study assessing Alecensa vs crizotinib for (ALK)-positive advanced NSCLC

Click here to read full press release/ article | Ref: Roche | Image: Deal Book

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post